APOE genotype and outcome in glioblastoma.

被引：0
|
作者：
Zunarelli, E
Rampling, R
Murray, LS
Stewart, J
Nicoll, JAR
机构：
[1] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[2] Univ Modena, I-41100 Modena, Italy
来源：
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY | 2001年 / 60卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
59
引用
收藏
页码：518 / 518
页数：1
相关论文
共 50 条
  • [41] Evaluation of the impact of necrosis on gene expression in glioblastoma.
    Dumur, CI
    Van Meter, TE
    Hafez, N
    Archer, KJ
    Ferreira-Gonzalez, A
    Wilkinson, DS
    Broaddus, WC
    Garrett, CT
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2005, 7 (05): : 682 - 682
  • [42] Outcome of traumatic brain injury after three decades - Relationship to ApoE genotype
    Isoniemi, Heli
    Tenovuo, Olli
    Portin, Raija
    Himanen, Leena
    Kairisto, Veli
    JOURNAL OF NEUROTRAUMA, 2006, 23 (11) : 1600 - 1608
  • [43] Long term neuropsychological outcome after head injury: relation to APOE genotype
    Millar, K
    Nicoll, JAR
    Thornhill, S
    Murray, GD
    Teasdale, GM
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (08): : 1047 - 1052
  • [44] Digital measurement of functional status of patients with glioblastoma.
    Damestani, Yasaman
    Mehta, Minesh P.
    Colman, Howard
    Camphausen, Kevin A.
    Weller, Michael
    Galanis, Evanthia
    Van Den Bent, Martin J.
    De Groot, John Frederick
    Lassman, Andrew B.
    Hottinger, Andreas Felix
    Nabors, Louis B.
    Duic, J. Paul
    Li, Kai
    Liu, Yang
    Tang, Shijie
    Tamir, Sharon
    Shacham, Eran
    Shah, Jatin J.
    Shacham, Sharon
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Circulating tumor cells as prognostic biomarkers in glioblastoma.
    Bark, Juliana Muller
    Kulasinghe, Arutha
    Leo, Paul
    Hartel, Gunter
    Warkiani, Majid E.
    Jeffree, Rosalind L.
    Chua, Benjamin
    Day, Bryan W.
    Punyadeera, Chamindie
    CANCER RESEARCH, 2021, 81 (13)
  • [46] Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma.
    Coy, Shannon
    Lin, Jia-Ren
    Wang, Shu
    Stopka, Sylwia
    Rashid, Rumana
    Hwang, Jaeho
    Khadka, Prasidda
    Euskirchen, Philipp
    Bandopadhayay, Pratiti
    Wen, Patrick Y.
    Sorger, Peter K.
    Agar, Nathalie
    Ligon, Keith L.
    Touat, Mehdi
    Santagata, Sandro
    CANCER RESEARCH, 2021, 81 (13)
  • [47] Profiling response to carmustine/bevacizumab in recurrent glioblastoma.
    Rojas, Leonardo
    Cardona, Andres F.
    Wills, Beatriz
    Arrieta, Oscar
    Vargas, Carlos A.
    Carranza, Hernan
    Otero, Jorge M.
    Useche, Nicolas
    Bermudez, Sonia
    Jimenez, Enrique
    Hakim, Fernando
    Balana, Carmen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Effect of Epo and EpoR expression on the Survival in Glioblastoma.
    Strik, H.
    Brunotte, J.
    Hemmerlein, B.
    Brueck, W.
    ONKOLOGIE, 2010, 33 : 59 - 60
  • [49] A preclinical study on the combined treatment of nimotuzumab and sirolimus in glioblastoma.
    Tham, Chee Kian
    Lam, Paula
    See, Siewju
    Lai, Siang Hui
    Thomas, John
    Ng, Wai Hoe
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Remote monitoring of sleep activity in patients diagnosed with glioblastoma.
    Noorvash, Brandon
    Amaral, L. J.
    Nelson, Thomas
    Rudnick, Jeremy David
    Irwin, Scott A.
    Freedland, Stephen J.
    Gresham, Gillian
    Hu, Jethro Lisien
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345